Convallatoxin
Convallatoxin, one cardiac glycoside, is a novel anti-angiogenic compound via dual inducing of autophagy and apoptosis, it shows antitumor effects that harbor inactivating mutations in the p53 signaling pathway. Convallatoxin as a novel antiviral, limiting mRNA translation has a dramatic impact on CMV infection and proliferation. Convallatoxin also anti-diabetic activity.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Anal Toxicol.2021, bkab015.
Green Chem.2023, 25:5222-5232
Applied Biological Chemistry2020, 63:33(2020)
J Korean Med Ophthalmol Otolaryngol Dermatol2023, 36(1):1-20.
Mol Biol Rep.2024, 51(1):56.
Antioxidants (Basel).2020, 9(6):544.
Biochem Biophys Res Commun.2020, 522(1):40-46
J Ethnopharmacol.2022, 291:115159.
Biomed Pharmacother.2019, 111:262-269
Curr Issues Mol Biol.2022, 44(5):2300-2308.
Related and Featured Products
Journal of Virology, 2016:90(23):1050-16.
Convallatoxin-Induced Reduction of Methionine Import Effectively Inhibits Human Cytomegalovirus Infection and Replication.[Reference:
WebLink]
Cytomegalovirus is a highly prevalent virus capable of causing severe disease in certain populations. The current FDA approved therapeutics all target the same stage of the viral life cycle and induce toxicity and viral resistance.
METHODS AND RESULTS:
We identified Convallatoxin, a novel, cell-targeting antiviral that inhibits CMV infection by decreasing the synthesis of viral proteins. At doses low enough for cells to tolerate, Convallatoxin was able to inhibit primary isolates of CMV, including those resistant to the anti-CMV drug ganciclovir. In addition to identifying Convallatoxin as a novel antiviral, limiting mRNA translation has a dramatic impact on CMV infection and proliferation.
Plos One, 2014, 9(3):e91094.
Convallatoxin, a Dual Inducer of Autophagy and Apoptosis, Inhibits Angiogenesis In Vitro and In Vivo.[Reference:
WebLink]
Autophagy and apoptosis are important processes that control cellular homeostasis and have been highlighted as promising targets for novel cancer therapies.
METHODS AND RESULTS:
Here, we identified Convallatoxin (CNT), isolated from Antiaris toxicaria, as a dual inducer of autophagy and apoptosis. CNT exerts cytotoxic effects on a number of cancer and normal cell lines and induces apoptosis by increasing caspase-3 and poly ADP ribose polymerase (PARP) cleavage. Moreover, dose- and time-dependent autophagic activity was detected in CNT-treated cells, and mammalian target of rapamycin (mTOR)/p70S6K signal pathway inhibition was observed. Notably, CNT inhibits human umbilical vein endothelial cell (HUVEC) growth and exerts anti-angiogenic activity in vitro and in vivo.
CONCLUSIONS:
Collectively, these results demonstrate that the naturally occurring compound, CNT, is a novel anti-angiogenic compound via dual inducing of autophagy and apoptosis.
Molecular Genetics & Metabolism Reports, 2017, 13:42-45.
The cardiac glycoside convallatoxin inhibits the growth of colorectal cancer cells in a p53-independent manner.[Reference:
WebLink]
Cardiac glycosides are plant-derived molecules that have shown antiproliferative properties against cancer cells, though the mechanism of action is not completely understood.
METHODS AND RESULTS:
We show that one cardiac glycoside, Convallatoxin, presents antiproliferative effects against colorectal cancer cells in culture and that the resulting cell death is independent of the p53 tumor suppressor.
CONCLUSIONS:
Our data suggest that Convallatoxin may be useful in the treatment of cancers that harbor inactivating mutations in the p53 signaling pathway.
Cell Death Discovery, 2017, 3:17009.
Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers.[Reference:
WebLink]
Breast cancer is second most prevalent cancer in women, and the second only to lung cancer in cancer-related deaths. It is a heterogeneous disease and has several subtypes based on the presence or absence of hormone receptors and/or human epidermal growth factor receptor 2 (HER2). Hormone receptor-positive and HER2-enriched cancers can be targeted using hormone and HER2-targeting therapies such as trastuzumab or lapatinib. However, triple-negative breast cancers (TNBCs) do not express any of the receptors and therefore are resistant to most targeted therapies, and cytotoxic chemotherapies are the only viable option available for the treatment of TNBCs. Recently, cardiac glycosides (CGs) have emerged as potential anticancer agents that impart their antiproliferative effect by targeting multiple pathways. In this study our aim was to evaluate anticancer effects of two naturally occurring CGs, Convallatoxin (CT) and Peruvoside (PS), on ER+ and TNBCs cells.
METHODS AND RESULTS:
CT and PS demonstrated dose- and time-dependent cytotoxic effect on MCF-7 cells, which was further supported by loss of colony formation on drug treatment. CT and PS arrested MCF-7 cells in the G0/G1 phase and reduced the viability of MCF-7-derived mammospheres (MMs). Interestingly, while CT and PS imparted cell death in TNBCs cells from both Caucasians (MDA-MB-231 cells) and African Americans (MDA-MB-468 cells) in a dose- and time-dependent manner, the drugs were much more potent in MDA-MB-468 as compared with TNBC MDA-MB-231 cells. Both drugs significantly inhibited migration and invasion of both MCF-7 and MDA-MB-468 cells. An assessment of intracellular pathways indicated that both drugs were able to modulate several key cellular pathways such as EMT, cell cycle, proliferation and cell death in both cell types.
CONCLUSIONS:
Our data suggest a promising role for CGs in breast cancer treatment specifically in targeting TNBCs derived from African Americans, and provides impetus for further investigation of the anticancer potential of this class of drugs.
